Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
Abstract
:1. Introduction
2. Results
2.1. Origin of Isolates
Isolates Were Collected from January 2019 to November 2020
2.2. Antimicrobial Susceptibility Patterns
Extended Spectrum Beta-Lactamase Producers and MDR Bacteria
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Paul, R. State of the Globe: Rising Antimicrobial Resistance of Pathogens in Urinary Tract Infection. J. Glob. Infect. Dis. 2018, 10, 117–118. [Google Scholar] [CrossRef] [PubMed]
- Behzadi, P.; Urbán, E.; Matuz, M.; Benkő, R.; Gajdács, M. The role of Gram-negative bacteria in urinary tract infections: Current concepts and therapeutic options. Adv. Exp. Med. Biol. 2021, 1323, 35–69. [Google Scholar] [CrossRef] [PubMed]
- Sugianli, A.K.; Ginting, F.; Parwati, I.; de Jong, M.D.; van Leth, F.; Schultsz, C. Antimicrobial resistance among uropathogens in the Asia-Pacific region: A systematic review. JAC Antimicrob. Resist. 2021, 3, dlab003. [Google Scholar] [CrossRef] [PubMed]
- Mortazavi-Tabatabaei, S.A.R.; Ghaderkhani, J.; Nazari, A.; Sayehmiri, K.; Sayehmiri, F.; Pakzad, I. Pattern of antibacterial resistance in urinary tract infections: A systematic review and meta-analysis. Int. J. Prev. Med. 2019, 10, 169. [Google Scholar] [CrossRef] [PubMed]
- Silva, A.; Costa, E.; Freitas, A.; Almeida, A. Revisiting the frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections. Antibiotics 2022, 11, 768. [Google Scholar] [CrossRef]
- Miranda-Novales, M.G.; Flores-Moreno, K.; López-Vidal, Y.; Rodríguez-Álvarez, M.; Solórzano-Santos, F.; Soto-Hernández, J.L.; Ponce de León-Rosales, S. UNCAR Network*. Antimicrobial resistance and antibiotic consumption in Mexican hospitals. Salud. Publica. Mex. 2020, 62, 42–49. [Google Scholar] [CrossRef]
- Garza-González, E.; Franco-Cendejas, R.; Morfín-Otero, R.; Echaniz-Aviles, G.; Rojas-Larios, F.; Bocanegra-Ibarias, P.; Flores-Treviño, S.; Ponce-De-León, A.; Rodríguez-Noriega, E.; Alavez-Ramírez, N.; et al. The Evolution of Antimicrobial Resistance in Mexico During the Last Decade: Results from the INVIFAR Group. Microb. Drug Resist. 2020, 26, 1372–1382. [Google Scholar] [CrossRef]
- Li, X.; Fan, H.; Zi, H.; Hu, H.; Li, B.; Huang, J.; Luo, P.; Zeng, X. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. J. Clin. Med. 2022, 11, 2817. [Google Scholar] [CrossRef]
- Amabile-Cuevas, C.F. Antibiotic usage and resistance in Mexico: An update after a decade of change. J. Infect. Dev. Ctries. 2021, 15, 442–449. [Google Scholar] [CrossRef]
- Zavala-Cerna, M.G.; Segura-Cobos, M.; Gonzalez, R.; Zavala-Trujillo, I.G.; Navarro-Perez, S.F.; Rueda-Cruz, J.A.; Santoscoy-Tovar, F.A. The clinical significance of high antimicrobial resistance in community-acquired urinary tract infections. Can J. Infect. Dis. Med. Microbiol. 2020, 2020, 2967260. [Google Scholar] [CrossRef]
- Paniagua-Contreras, G.L.; Monroy-Pérez, E.; Bautista, A.; Reyes, R.; Vicente, A.; Vaca-Paniagua, F.; Díaz, C.E.; Martínez, S.; Domínguez, P.; García, L.R.; et al. Multiple antibiotic resistances and virulence markers of uropathogenic Escherichia coli from Mexico. Pathog. Glob. Health 2018, 112, 415–420. [Google Scholar] [CrossRef] [PubMed]
- Ramírez-Castillo, F.Y.; Moreno-Flores, A.C.; Avelar-González, F.J.; Márquez-Díaz, F.; Harel, J.; Guerrero-Barrera, A.L. An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: Cross-sectional study. Ann. Clin. Microbiol. Antimicrob. 2018, 17, 34. [Google Scholar] [CrossRef] [PubMed]
- Lagunas-Rangel, F.A. Antimicrobial susceptibility profiles of bacteria causing urinary tract infections in Mexico: Single-centre experience with 10 years of results. J. Glob. Antimicrob. Resist. 2018, 14, 90–94. [Google Scholar] [CrossRef] [PubMed]
- Patwardhan, V.; Singh, S. Fosfomycin for the treatment of drug-resistant urinary tract infections: Potential of an old drug not explored fully. Int. Urol. Nephrol. 2017, 49, 1637–1643. [Google Scholar] [CrossRef]
- Albán, M.V.; Mariño-Brito, E.; Villavicencio, F.; Satán, C.; Villacís, J.E.; Gestal, M.C. Fosfomycin, applying known methods and remedies to a new era. Diseases 2020, 8, 31. [Google Scholar] [CrossRef]
- Moghnia, O.H.; Al-Sweih, N.A. Whole genome sequence analysis of multidrug resistant Escherichia coli and Klebsiella pneumoniae strains in Kuwait. Microorganisms 2022, 10, 507. [Google Scholar] [CrossRef]
- Abbott, I.J.; Peel, T.N.; Cairns, K.A.; Stewardson, A.J. Antibiotic management of UTI in the post-antibiotic era: A narrative review highlighting diagnostic and antimicrobial stewardship. Clin. Microbiol. Infect. 2022, S1198-743X(22)00272-5. [Google Scholar] [CrossRef]
- Kulchavenya, E. The best rules for antimicrobial stewardship in urogenital tract infections. Curr. Opin. Urol. 2020, 30, 838–844. [Google Scholar] [CrossRef]
- Diagnóstico y tratamiento de la infección de vías urinarias no complicada en menores de 18 años en el primer y segundo niveles de atención. In Guía de Práctica Clínica: Evidencias y Recomendaciones; CENETEC: Mexico City, Mexico, 2021. Available online: http://www.cenetec-difusion.com/CMGPC/GPC-SS027-21/ER.pdf (accessed on 8 August 2022).
- Diagnóstico y Tratamiento de la Infección Aguda, no Complicada del Tracto Urinario de la Mujer México: Instituto Mexicano del Seguro Social 2009. Available online: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/077GER.pdf (accessed on 8 August 2022).
- Ballesteros-Monrreal, M.G.; Arenas-Hernández, M.M.; Enciso-Martínez, Y.; Martínez-de la Peña, C.F.; Rocha-Gracia, R.D.C.; Lozano-Zaraín, P.; Navarro-Ocaña, A.; Martínez-Laguna, Y.; de la Rosa-López, R. Virulence and resistance determinants of uropathogenic Escherichia coli strains isolated from pregnant and non-pregnant women from two states in Mexico. Infect. Drug Resist. 2020, 13, 295–310. [Google Scholar] [CrossRef] [Green Version]
- Wagenlehner, F.; Tandogdu, Z.; Bartoletti, R.; Cai, T.; Cek, M.; Kulchavenya, E.; Köves, B.; Naber, K.; Perepanova, T.; Tenke, P.; et al. The Global prevalence of infections in urology study: A long-term, worldwide surveillance study on urological infections. Pathogens 2016, 5, 10. [Google Scholar] [CrossRef]
- Mazzariol, A.; Bazaj, A.; Cornaglia, G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: A review. J. Chemother. 2017, 29, 2–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pierantoni, L.; Andreozzi, L.; Ambretti, S.; Dondi, A.; Biagi, C.; Baccelli, F.; Lanari, M. Three-Year Trend in Escherichia coli Antimicrobial Resistance among Children’s Urine Cultures in an Italian Metropolitan Area. Children 2021, 8, 597. [Google Scholar] [CrossRef] [PubMed]
- Fan, N.C.; Chen, H.H.; Chen, C.L.; Ou, L.S.; Lin, T.Y.; Tsai, M.H.; Chiu, C.H. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J. Microbiol. Immunol. Infect. 2014, 47, 399–405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Autore, G.; Neglia, C.; Di Costanzo, M.; Ceccoli, M.; Vergine, G.; La Scola, C.; Malaventura, C.; Falcioni, A.; UTI-Ped-ER Study Group. Clinical Outcome of Discordant Empirical Therapy and Risk Factors Associated to Treatment Failure in Children Hospitalized for Urinary Tract Infections. Children 2022, 9, 128. [Google Scholar] [CrossRef] [PubMed]
- Goebel, M.C.; Trautner, B.W.; Grigoryan, L. The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. Clin. Microbiol. Rev. 2021, 34, e0000320. [Google Scholar] [CrossRef]
- Nedved, A.; Lee, B.R.; Hamner, M.; Wirtz, A.; Burns, A.; El Feghaly, R.E. Impact of an antibiotic stewardship program on antibiotic choice, dosing, and duration in pediatric urgent cares. Am. J. Infect. Control. 2022, S0196-655300597-1. [Google Scholar] [CrossRef]
- Muratore, E.; Baccelli, F.; Leardini, D.; Campoli, C.; Belotti, T.; Viale, P.; Prete, A.; Pession, A.; Masetti, R.; Zama, D. Antimicrobial Stewardship Interventions in Pediatric Oncology: A Systematic Review. J. Clin. Med. 2022, 11, 4545. [Google Scholar] [CrossRef]
- Loubet, P.; Ranfaing, J.; Dinh, A.; Dunyach-Remy, C.; Bernard, L.; Bruyère, F.; Lavigne, J.P.; Sotto, A. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. Front. Microbiol. 2020, 11, 1509. [Google Scholar] [CrossRef]
- De Nunzio, C.; Bartoletti, R.; Tubaro, A.; Simonato, A.; Ficarra, V. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics 2021, 10, 373. [Google Scholar] [CrossRef]
- Clinical and Laboratory Standards Institute (CLSI) M100—Performance Standards for Antimicrobial Susceptibility Testing, 31st ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 20 September 2021; Available online: https://clsi.org/media/3481/m100ed30_sample.pdf (accessed on 20 September 2022).
- Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef]
Name of Hospital or Institution (Location) | Type of Hospital | Number of Beds |
---|---|---|
1. Instituto Nacional de Neurología y Neurocirugía “Dr. Manuel Velasco Suárez” (Mexico City) | Specialty (neurology and neurosurgery) | 126 |
2. Instituto Nacional de Cancerología (Mexico City) | Specialty (oncology) | 188 |
3. Instituto Nacional de Cardiología “Dr. Ignacio Chávez” (Mexico City) | Specialty (cardiology) | 213 |
4. Hospital General “Dr. Manuel Gea González” (Mexico City) | General | 107 |
5. UMAE Hospital de Cardiología “Dr. Luis Méndez”, Centro Médico Nacional Siglo XXI, IMSS (Mexico City) | Specialty (cardiology) | 170 |
6. Hospital Civil de Guadalajara “Fray Antonio Alcalde” (Jalisco) | General | 843 |
7. Hospital General Regional Nº 200 Tecámac, IMSS (State of Mexico) | General (regional) | 249 |
8. Hospital General de México “Dr. Eduardo Liceaga” (Mexico City) | General | 842 |
9. Hospital General de Durango (Durango) | General | 126 |
10. UMAE 34 Hospital de Cardiología Monterrey, IMSS (Nuevo León) | Specialty (cardiology) | 200 |
11. Hospital Regional de Alta Especialidad del Bajío (Guanajuato) | Tertiary-care (regional) | 184 |
12. Hospital Central Sur de Alta Especialidad de Petróleos Mexicanos (Mexico City) | Tertiary-care | 140 |
13. Laboratorios Ruiz (Puebla) | Private laboratory | Not applicable |
14. Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra” (Mexico City) | Specialty | 228 |
15. UMAE de Pediatría, Centro Médico Nacional Siglo XXI, IMSS (Mexico City) | Specialty (pediatric) | 184 |
16. Asesores Especializados en Laboratorios, Puebla (AEL) | Private laboratory | Not applicable |
17. Hospital Aranda de la Parra (Guanajuato) | Private | 109 |
18. CARPERMOR. Laboratorio de Referencia Internacional (International Reference Laboratory) | Private laboratory | Not applicable |
19. Hospital del Niño Morelense (Morelos) | Specialty (pediatric) | 38 |
20. Instituto Nacional de Enfermedades Respiratorias “Dr. Ismael Cosío Villegas” (Mexico City) | Specialty (pulmonology) | 175 |
21. Hospital Pediátrico de la Villa (Mexico City) | General (pediatric) | 53 |
Escherichia coli n = 156 | Klebsiella pneumoniae n = 82 | |||||
---|---|---|---|---|---|---|
ESBL+ | ESBL- | ESBL+ | ESBL- | p Value ** | ||
Total | 56% (87) | 44% (69) | 52% (43) | 48% (39) | 0.62 | |
Antibiotic | % Resistant isolates (n) | p value | % Resistant isolates (n) | p value | ||
Ampicillin/ Sulbactam | 92 (80) | 62 (43) | 0.00003 | 100 (43) | 35.9 (14) | <0.00001 |
Amikacin | 1 (1) | 0 (0) | NA | 2 (1) | 0 (0) | NA |
Gentamicin | 47 (41) | 23 (15) | 0.001 | 61 (26) | 5 (2) | <0.00001 |
Ciprofloxacin | 95 (83) | 54 (37) | <0.00001 | 88 (38) | 26 (10) | <0.00001 |
Norfloxacin | 90 (51) | 47 (23) | <0.00001 | 25 (7) | 13 (4) | 0.22 |
Nitrofurantoin | 10 (8) | 6 (4) | 0.31 | 85(35) | 50 (19) | 0.0008 |
TMP/SMZ | 63 (53) | 61 (40) | 0.76 | 85 (35) | 13 (5) | <0.00001 |
Fosfomycin | 14 (12) | 7 (5) | 0.19 | 7 (3) | 13 (5) | 0.3 |
Chloramphenicol (Kirby–Bauer) | 26 (23) | 16 (11) | 0.11 | 16 (7) | 15 (6) | 0.91 |
Resistance Characteristic * | Escherichia coli | Klebsiella pneumoniae | p Value | ||
---|---|---|---|---|---|
N | % | N | % | ||
Two | 45 | 29 | 30 | 36 | 0.22 |
MDR | 106 | 68 | 39 | 48 | 0.002 |
XDR | 5 | 3 | 13 | 16 | 0.0004 |
PDR | 0 | 0 | 0 | 0 | - |
Total (n) | 156 | 100 | 82 | 100 |
Escherichia coli | Klebsiella pneumoniae | |||||||
---|---|---|---|---|---|---|---|---|
Adult (n = 133) | Pediatric (n = 23) | Adult (n = 74) | Pediatric (n = 8) | |||||
ESBL+ | ESBL- | ESBL+ | ESBL- | ESBL+ | ESBL- | ESBL+ | ESBL- | |
Total | 73 (55%) | 60 (45%) | 14 (61%) | 9 (39%) | 37 (50%) | 37 (50%) | 7 (87%) | 1 (13%) |
Antibiotic | Resistance % | |||||||
Ampicillin/ sulbactam | 90 | 65 | 100 | 44 | 100 | 32 | 86 | 100 |
Amikacin | 1 | 0 | 0 | 0 | 0 | 0 | 28 | 0 |
Gentamicin | 48 | 23 | 43 | 0 | 57 | 5 | 86 | 0 |
Ciprofloxacin | 90 | 55 | 93 | 11 | 86 | 24 | 43 | 0 |
Nitrofurantoin | 11 | 7 | 0 | 0 | 84 | 49 | 62 | 100 |
TMP/SMZ | 59 | 58 | 93 | 66 | 89 | 16 | 62 | 0 |
Fosfomycin | 5 | 5 | 28 | 0 | 8 | 13 | 0 | 0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Miranda-Novales, G.; Flores-Moreno, K.; López-Vidal, Y.; Ponce de León-Rosales, S.; PUCRA Network Members. Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections. Antibiotics 2022, 11, 1656. https://doi.org/10.3390/antibiotics11111656
Miranda-Novales G, Flores-Moreno K, López-Vidal Y, Ponce de León-Rosales S, PUCRA Network Members. Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections. Antibiotics. 2022; 11(11):1656. https://doi.org/10.3390/antibiotics11111656
Chicago/Turabian StyleMiranda-Novales, Guadalupe, Karen Flores-Moreno, Yolanda López-Vidal, Samuel Ponce de León-Rosales, and PUCRA Network Members. 2022. "Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections" Antibiotics 11, no. 11: 1656. https://doi.org/10.3390/antibiotics11111656